The trial, sponsored by Peking University People's Hospital, aims to address a significant unmet need in the management of CMV infections following haploidentical stem cell transplantation. Given the high incidence of CMV-related complications, successful outcomes could position the expanded NK cell therapy as a critical intervention in the transplant market, potentially leading to improved patient survival and reduced healthcare costs. The competitive landscape includes other immunotherapeutic approaches targeting viral infections post-transplant, but the unique mechanism of action involving NK cell expansion may provide a differentiated offering. Diligence should focus on regulatory pathways, reimbursement strategies, and potential partnerships for commercialization.